AbCellera Biologics Inc.
ABCL
Kedudukan dalam Saham
#4145
AbCellera Biologics Inc. specializes in pioneering an advanced platform for the... AbCellera Biologics Inc. specializes in pioneering an advanced platform for the discovery of antibodies. This comprehensive, AI-driven system meticulously explores and analyzes natural immune systems to identify antibodies suitable for the creation of new pharmaceutical drugs. As of December 31, 2021, the company had cultivated 156 discovery programs, ranging from completed to in-progress or under contract, in partnership with 36 entities. Notably, AbCellera maintains a crucial research collaboration and license agreement with Eli Lilly and Company. Founded in 2012, the firm is headquartered in Vancouver, Canada.
Harga Saham
$11.99
Disegerakkan terakhir: 2026-10-19
Modal Pasaran
$3.88B
Perubahan (1 hari)
1.57%
Perubahan (1 tahun)
104.52%
Negara
CA
Perdagangan AbCellera Biologics Inc. (ABCL)
Kategori
Healthcare
Bilangan saham terbitan bagi AbCellera Biologics Inc. (ABCL)
Bilangan saham terbitan setakat June 2026: 305.56M
Menurut laporan kewangan terkini dan harga saham AbCellera Biologics Inc., bilangan saham terbitan semasa ialah 305.56M. Pada akhir December 2023, syarikat mempunyai 289.17M saham terbitan. Bilangan saham terbitan biasanya dipengaruhi oleh pecahan saham dan pembelian balik saham.
Sejarah saham terbitan untuk AbCellera Biologics Inc. (ABCL) dari 2018 hingga 2026
Saham terbitan pada akhir setiap tahun
| Tahun | Saham Terbitan | Ubah |
|---|---|---|
| 2026 (TTM) | 305.56M | 3.82% |
| 2024 | 294.33M | 1.78% |
| 2023 | 289.17M | 1.44% |
| 2022 | 285.06M | 3.37% |
| 2021 | 275.76M | 2.96% |
| 2020 | 267.82M | 24.33% |
| 2019 | 215.41M | 42.60% |
| 2018 | 151.06M | 0.00% |
Saham terbitan bagi syarikat atau pesaing yang serupa
| Syarikat | Saham Terbitan | Perbezaan | Negara |
|---|---|---|---|
| 253.90M | -16.91% |
US
|
|
| 396.00M | 29.60% |
US
|
|
| 478.91M | 56.73% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -79.65% |
NL
|
